Of particular interest is Mrp2/Abcc2, which is decreased in several rodent models of obesity, NAFLD and NASH and is normalized upon rosiglitazone treatment (Geier et al., 2005; Fisher et al., 2009a; Martin et al., 2010). This evidence concerns the gene ABCC2 and metabolic dysfunction-associated steatotic liver disease.